CLLS Q2 2025: Cash Runway Extends to H2 2027 as Pivotal Trials Advance
Selectis sharpened its late-stage pipeline focus this quarter, securing regulatory clarity for its pivotal UCART22 trial and maintaining a cash runway into H2 2027. The upcoming October R&D Day is set to reveal key Phase 1 data and late-stage strategies. Arbitration with Servier and AstraZeneca partnership progress remain material watchpoints for the business trajectory.
Summary
- Regulatory Alignment Secured: FDA and EMA feedback confirmed a clear path for pivotal UCART22 trials.
- Cash Position Underpins Execution: Sufficient resources to fund operations and pivotal trials through H2 2027.
- Late-Stage Data and Arbitration Loom: R&D Day and Servier arbitration outcomes will shape Selectis’ near-term valuation.
Business Overview
Selectis is a clinical-stage biotechnology company specializing in allogeneic CAR-T therapies, a form of cell therapy where donor-derived T-cells are engineered to target cancer and can be delivered off-the-shelf. The company’s main programs include UCART22 (Lasmucil) for relapsed/refractory acute lymphoblastic leukemia (ALL) and UCART20x22 (Eticell) for non-Hodgkin’s lymphoma, alongside three partnered cell and gene therapy programs with AstraZeneca. Revenue is primarily generated through collaboration agreements, milestone payments, and R&D partnerships.
Performance Analysis
Selectis maintained a robust cash position, reporting $230 million in cash, equivalents, and deposits as of June 30, 2025, down from $264 million at year-end. The decrease reflects ongoing investment in R&D, clinical operations, and workforce, partially offset by revenue and interest income. Management emphasized that this runway is sufficient to fund both pivotal studies for Lasmucil and Eticell into the second half of 2027, providing rare multi-year visibility for a clinical-stage biotech.
Operationally, the company completed Phase 1 for UCART22, secured positive and aligned feedback from both the FDA and EMA, and is now preparing for a pivotal Phase 2 trial in ALL. The Eticell program continues to recruit in non-Hodgkin’s lymphoma, with data readouts expected later this year. R&D partnership activity with AstraZeneca remains on track, spanning hematological malignancies, solid tumors, and in vivo gene therapy. Selectis is also navigating an ongoing arbitration with Servier regarding CD19 product rights and milestone claims, with a decision expected by year-end.
- Cash Burn Driven by R&D Execution: Operating outflows were mainly attributed to supplier payments and personnel costs, reflecting active pipeline advancement.
- Pipeline Progression Anchors Valuation: Transition to pivotal trials and regulatory clarity are key value inflection points.
- Non-Dilutive Funding Potential: Current runway does not factor in upside from future milestones or non-dilutive capital, which could extend cash further.
With pivotal clinical milestones and a resolved cash position, Selectis is positioned to weather near-term biotech volatility, though late-stage data and legal outcomes will determine the next phase of value creation.
Executive Commentary
"We are excited to prepare for the initiation of a pivotal phase two trial for lasmosis cell, UCAR T22, in relapsed or refractory acute lymphoblastic leukemia in the second half of this year."
Dr. André Choulika, Chief Executive Officer
"Our cash, cash equivalents and fixed-term deposits as of June 30th, 2025 remain sufficient to fund our operations into H2 2027."
Arthur Strill, Chief Financial Officer and Chief Business Officer
Strategic Positioning
1. Pivotal Trial Readiness and Regulatory Clarity
FDA and EMA alignment on endpoints, statistical plans, and patient populations for UCART22 removes a major uncertainty for Selectis. The company’s ability to secure clear regulatory feedback and establish a path to registration supports its transition toward late-stage development and potential commercialization.
2. Pipeline Differentiation and Expansion
Eticell (UCART20x22) positions Selectis uniquely in the dual-targeting CAR-T space by avoiding CD19 and targeting CD20 and CD22, which may address patient populations relapsing after CD19 therapies. This approach is distinct from autologous and other allogeneic competitors, and could become more relevant as CD19 therapies move earlier in treatment lines.
3. Capital Efficiency and Risk Mitigation
Selectis’ multi-year cash runway is a strategic asset, reducing near-term financing risk and enabling focus on clinical execution. The company’s financial planning prudently excludes uncommitted milestone revenue, positioning it to absorb R&D volatility and legal outcomes without forced dilution or program delays.
4. Strategic Partnerships and Legal Leverage
The AstraZeneca collaboration provides access to external capital and validation, while the Servier arbitration could unlock CD19 product rights or compensation. Both are potential catalysts, but also introduce binary risk that investors must monitor closely.
5. Manufacturing and Supply Chain Readiness
In-house manufacturing capabilities are highlighted as a competitive advantage, supporting both current trials and future commercialization efforts as the pipeline matures.
Key Considerations
With pivotal trials commencing and several catalysts on the horizon, Selectis’ execution in the coming quarters will be pivotal for investor confidence and valuation.
Key Considerations:
- Regulatory Milestones in Focus: Clear FDA and EMA alignment on pivotal trial design for UCART22 de-risks the path to registration.
- R&D Day as a Value Catalyst: October’s event will provide critical data transparency and late-stage strategy details, shaping investor expectations.
- Legal Outcome Uncertainty: The Servier arbitration could impact Selectis’ pipeline breadth and financial position, depending on tribunal outcomes.
- Cash Runway Shields Against Dilution: Multi-year funding reduces pressure for near-term capital raises, a notable advantage in the current biotech climate.
- Dual-Targeting Differentiation: Eticell’s non-CD19 approach could address new segments as treatment paradigms evolve.
Risks
Key risks include binary clinical trial outcomes, regulatory delays, and the uncertainty of the Servier arbitration, which could affect both pipeline scope and financials. Competitive dynamics in the CAR-T space, especially from autologous and other allogeneic entrants, remain intense. Macro biotech funding volatility and the need for additional capital beyond 2027 are longer-term considerations.
Forward Outlook
For Q3 and the second half of 2025, Selectis guided to:
- Commence pivotal Phase 2 trial for UCART22 in relapsed/refractory ALL.
- Present comprehensive Phase 1 UCART22 data and late-stage strategy at October R&D Day.
For full-year 2025, management maintained guidance:
- Cash runway sufficient into H2 2027, inclusive of pivotal trial costs.
Management flagged upcoming milestones:
- ASH conference submissions for both lead programs.
- Arbitration decision with Servier expected by December 15, 2025.
Takeaways
- Pivotal Transition: Regulatory clarity and trial site expansion set the stage for late-stage clinical readouts in ALL and NHL, with high unmet need populations.
- Financial Buffer: Selectis’ cash position provides rare visibility and reduces execution risk amid sector-wide funding headwinds.
- Catalyst-Heavy Second Half: R&D Day, ASH data, and legal outcomes are likely to drive sentiment and valuation in the months ahead.
Conclusion
Selectis enters the second half of 2025 with regulatory clarity, late-stage pipeline momentum, and a fortified balance sheet. The upcoming R&D Day and arbitration resolution will be critical in shaping the next phase of the company’s growth and investor narrative.
Industry Read-Through
Selectis’ regulatory progress and capital discipline signal a maturing allogeneic CAR-T field, where late-stage clarity and differentiated targeting are increasingly required for competitive positioning. The shift toward broader, later-line patient populations and dual-targeting approaches reflects a sector-wide move to address post-CD19 relapse and expand market opportunities. Cash runway visibility is emerging as a key differentiator for clinical-stage biotechs, especially as capital markets remain selective. The outcome of arbitration and partnership dynamics will be closely watched by peers and investors assessing IP risk and the value of cross-pharma collaborations.